ClinicalTrials.gg
RecruitingNCT07278440Updated Oct 28, 2026

An Exercise Intervention for Improving Mental and Physical Health in Patients With Primary Brain Tumors and Their Caregivers, ET-NEURO Trial

An interventional study of Electronic Health Record Review and Magnetic Resonance Imaging in Primary Brain Neoplasm, sponsored by OHSU Knight Cancer Institute. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by OHSU Knight Cancer Institute · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 2 months later.
Updated Oct 28, 2026Start date movedEligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Brain Neoplasms by OHSU Knight Cancer Institute — 1 open to participants now, 2 under way, none of them phase 3. Brain Neoplasms · OHSU Knight Cancer Institute.

Planned enrollment
5th of 11
36 · median 21
Started
2026
the only one that year
No phase
3 of 11
1 open now
Registered
11th of 11
by date

Among the 11 studies in Brain Neoplasms by OHSU Knight Cancer Institute, this one is the 5th largest by planned enrollment, is the only one that started in 2026, is one of 3 with no phase, and was the 11th registered.

Brain Neoplasms

2,447 studies on the registry are indexed under Brain Neoplasms; 546 are open to participants now.

Browse Brain Neoplasms studies →

Open to participants now

1 of the 11 studies in Brain Neoplasms by OHSU Knight Cancer Institute is open now, in 1 country.

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 429 Brain Neoplasms studies recruiting now, 289 (67%) set no upper age limit and 83 (19%) stop at 75 or younger; 80 take children under 18; 37 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Brain Neoplasms by OHSU Knight Cancer Institute, or all of them as a file.
02

Study summary

This clinical trial evaluates the effects of a partnered exercise program, called Exercise Together, on participants with primary brain tumors and their caregivers. Standard treatments for primary brain tumors require extensive caregiver support, and both patients and caregivers experience high psychological distress and physical burden as a result. While exercise is known to improve outcomes in cancer patients, its impact on primary brain tumor patients and caregivers remains unstudied. Exercise Together is a supervised, group exercise program previously studied in patients with other types of cancer, though never in patients with primary brain tumors or their caregivers. Exercise Together uses functional resistance training to target muscle groups essential for everyday activities to improve daily functioning. Since exercises are done in a partnered format, Exercise Together is also designed to foster teamwork and strengthen the relationship between the patient and their caregiver. This program may be safe, feasible, and effective in improving the mental and physical health of primary brain tumor patients and their caregivers.

Read the detailed description

PRIMARY OBJECTIVE:

I. To assess the safety and feasibility of the Exercise Together program for patient-participants with a diagnosis of primary brain tumor and their caregiver-participants.

SECONDARY OBJECTIVE:

I. To preliminarily evaluate the impact of the Exercise Together program on enhancing patient-caregiver relationships and improving quality of life in dyads affected with primary brain tumor (PBT).

EXPLORATORY OBJECTIVE:

I. To investigate the changes in the central nervous system (CNS) glymphatic system before, during, and after the exercise program and its association with cognition.

OUTLINE:

Patients and caregivers participate in Exercise Together virtual resistance training sessions, over 75 minutes each, twice weekly for 12 weeks. Patients may undergo magnetic resonance imaging (MRI) throughout the study as part of their standard care.

After completion of study intervention, participants are followed up at 4 weeks and then monthly in months 1-4.

03

Conditions studied

  • Primary Brain Neoplasm

Browse trials for

04

Who can participate

The criteria were revised on the registry on Oct 28, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • PATIENT INCLUSION:
  • Patient participants must have a diagnosis of World Health Organization (WHO) grade 1-4 PBT such as glioblastoma, astrocytoma, oligodendroglioma, ependymoma, medulloblastoma, meningioma, and other primary brain tumors as determined by the treating physician/neuro-oncologist. Confirmed by review of the electronic medical record (EMR) and subsequently recorded in health history questionnaire. In cases where the EMR isn't clear, their Oregon Health \& Science University OHSU provider will be contacted for confirmation
  • Patient participants on active oral chemotherapy, including cytotoxic chemotherapy and molecularly targeted therapy, for the treatment of PBT are allowed
  • Patient participants must be at least 6 weeks after the last dose of intravenous infusion chemotherapy for the treatment of PBT, including bevacizumab, prior to enrollment
  • Patient participants must be at least 6 weeks post-radiation for PBT prior to enrollment. Patient participants must be at least 8 weeks post-craniotomy prior to enrollment
  • Patient participants must have a co-residing spouse or partner caregiver due to the program's focus on intimacy
  • Patient participants must have a performance score of at least 70 or an (ECOG) score of 1 or less
  • Patient participants are permitted to participate in other therapeutic interventional clinical trials for PBT
  • PATIENT AND CAREGIVER INCLUSION:
  • Patient participants and caregiver participants must be 18 years of age or older
  • Patient participants and caregiver participants must state willingness to comply with all study procedures and availability for the duration of the study
  • Patient participants and caregiver participants must have the ability to understand and the willingness to sign a written document
  • Patient participants and caregiver participants must have home internet sufficient for videoconferencing

Exclusion criteria

Exclusion Criteria:

  • PATIENT AND CAREGIVER EXCLUSION:
  • Patient participants must not have engaged in two or more regular strength training sessions per week (e.g., physical therapy) during the past 30 days, as confirmed by self-report on the health history questionnaire. Caregiver participants are allowed to engage in strength training outside of the program
  • Patient participants and caregiver participants with cognitive difficulties preclude answering survey questions. In the event of a suspected undeclared cognitive impairment, it will be confirmed by physician clearance or professional opinion of the principal investigator
  • Because this exercise intervention has not been evaluated in pregnant populations and the study team cannot provide the enhanced monitoring needed to ensure maternal and fetal safety, participants who are pregnant or planning pregnancy are excluded
  • Patient participants and caregiver participants with medical condition, movement condition, pre-existing focal neurological deficits, new focal deficits concerning for recurrent or progressive PBT necessitating treatment, post operative deficits/wound, or medication use that contraindicates participation in moderate intensity exercise. Specific include the following: poorly controlled diabetes, recent cardiac event, neuromuscular disease, untreated orthostatic hypertension, recent surgery, acute hernia, acute rheumatoid arthritis, severe memory disorders, severe balance disorder, inability to ambulate without a walker or wheelchair, inability to stand for 3 minutes, severe hearing or vision problem

    • Confirmed by a combination of reviewing the EMR, self-report on the health history questionnaire, and/or by physician clearance. All patient participants will receive physician clearance by the neuro-oncology investigators prior to participating in the trial. For caregiver participants: must answer 'No' to American College of Sports Medicine pre-participation screening questions. If caregiver participants answer 'Yes' to either question they may be required to obtain physician clearance prior to being considered eligible. Physician clearance may also be requested at the discretion of the principal investigator
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    Supportive care (Exercise Together)

    Patients and caregivers participate in Exercise Together virtual resistance training sessions, over 75 minutes each, twice weekly for 12 weeks. Patients may undergo MRI throughout the study as part of their standard care.

    Other: Electronic Health Record Review · Procedure: Magnetic Resonance Imaging · Other: Questionnaire Administration · Other: Resistance Training

Interventions

  • OtherElectronic Health Record Review

    Ancillary studies

  • ProcedureMagnetic Resonance Imaging

    Undergo MRI

    Also known as: Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI

  • OtherQuestionnaire Administration

    Ancillary studies

  • OtherResistance Training

    Participate in Exercise Together

    Also known as: Strength Training

06

What researchers measure

Primary outcomes

  1. Enrollment rate (feasibility)

    Feasibility will be evaluated using an enrollment rate of ≥ 50% of eligible patient-caregiver dyads. Continuous variables will be characterized by N, mean or median, standard deviation or interquartile range; and discrete variables will be characterized by frequencies and proportions with exact 95% confidence intervals, as appropriate.

    Time frame: Following screening at baseline

  2. Adherence (feasibility)

    Feasibility will be evaluated using adherence, which will be defined as ≥ 50% of enrolled dyads completing at least 50% of the prescribed sessions (i.e., both members of the dyads attend ≥ 12 of 24 supervised exercise sessions). Continuous variables will be characterized by N, mean or median, standard deviation or interquartile range; and discrete variables will be characterized by frequencies and proportions with exact 95% confidence intervals, as appropriate.

    Time frame: Up to 12 weeks

  3. Retention (feasibility)

    Feasibility will be evaluated using a retention rate of ≥ 50%. Continuous variables will be characterized by N, mean or median, standard deviation or interquartile range; and discrete variables will be characterized by frequencies and proportions with exact 95% confidence intervals, as appropriate.

    Time frame: Up to 4 weeks after intervention completion

  4. Incidence of adverse events

    Defined as grade 3 or higher adverse events in both patient-participants and caregiver-participants, as per Common Terminology Criteria for Adverse Events version 5.0, directly attributable to the study intervention during the Exercise Together program. Continuous variables will be characterized by N, mean or median, standard deviation or interquartile range; and discrete variables will be characterized by frequencies and proportions with exact 95% confidence intervals, as appropriate.

    Time frame: Up to 1-month post-exercise intervention

Secondary outcomes

  1. Quality of life

    Appropriate summary statistics (e.g., mean or median, standard deviation or interquartile range) will be used to characterize quality of life measures at each time point for the following questionnaires for patient participants: Distress Thermometer (DT), Functional Assessment of Chronic Illness Therapy fatigue questionnaire, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 together with the brain tumor-specific module and cancer loneliness scale. For caregiver participants, will use the following: DT, Short Form-36 questionnaire physical functioning subscale, as well as Caregiver Quality of Life Index-Cancer scale and the caregiver cancer loneliness scale. Continuous variables will be characterized by N, mean or median, standard deviation or interquartile range; and discrete variables will be characterized by frequencies and proportions with exact 95% confidence intervals, as appropriate.

    Time frame: At baseline, 6 weeks, 12 weeks, and 16 weeks

  2. Patient and caregiver relationship quality

    Will be measured using the dyadic coping measure. A linear mixed model will be used to quantify the trend over time and estimate the changes from baseline to each follow up time point. Hypothesis tests may be conducted for exploratory purposes and signal detection. Variation of time trend by patient characteristics may also be explored cautiously. Model assumptions will be checked and if not satisfied, alternative methods will be used. Continuous variables will be characterized by N, mean or median, standard deviation or interquartile range; and discrete variables will be characterized by frequencies and proportions with exact 95% confidence intervals, as appropriate.

    Time frame: At baseline, 6 weeks, 12 weeks, and 16 weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for May 2027, 8 months after the start.

Of 310 non-industry interventional studies with no phase under Brain Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 126. This study's planned 8 months is below that.

Counting every sponsor, half of 321 studies reached it within 64 months; a quarter within 35 and three quarters within 125.

Start moved once since we started tracking on Sep 25, 2026: Jul 2026 → Aug 2026, on Oct 28, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2025
First posted
Dec 12, 2025
StartActual
Aug 24, 2026was Jul 2026
Primary completionEst.
May 2, 2027
CompletionEst.
Aug 2, 2027
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jul 10, 2026→Aug 24, 2026
Oct 28, 2026
Eligibility
1 inclusion criterion edited; 1 exclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedPatient participants must have a histologically confirmed diagnosis of World Health Organization (WHO) grade 1-4 PBT such as glioblastoma, astrocytoma, oligodendroglioma, ependymoma, medulloblastoma, meningioma, and other primary brain tumors as determined by the treating physician/neuro-oncologist. Confirmed by review of the electronic medical record (EMR) and subsequently recorded in health history questionnaire. In cases where the EMR isn't clear, their Oregon Health \& Science University OHSU provider will be contacted for confirmation
Exclusion criteria
  • EditedPatient and caregiver participants must not have engaged in two or more regular strength training sessions per week (e.g., physical therapy) during the past 30 days, as confirmed by self-report on the health history questionnaire. Caregiver participants are allowed to engage in strength training outside of the program
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Start date Jul 10, 2026→Aug 24, 2026
    Eligibility 1 inclusion criterion edited; 1 exclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedPatient participants must have a histologically confirmed diagnosis of World Health Organization (WHO) grade 1-4 PBT such as glioblastoma, astrocytoma, oligodendroglioma, ependymoma, medulloblastoma, meningioma, and other primary brain tumors as determined by the treating physician/neuro-oncologist. Confirmed by review of the electronic medical record (EMR) and subsequently recorded in health history questionnaire. In cases where the EMR isn't clear, their Oregon Health \& Science University OHSU provider will be contacted for confirmation
    Exclusion criteria
    • EditedPatient and caregiver participants must not have engaged in two or more regular strength training sessions per week (e.g., physical therapy) during the past 30 days, as confirmed by self-report on the health history questionnaire. Caregiver participants are allowed to engage in strength training outside of the program
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07278440
Collaborators
National Cancer Institute (NCI), Oregon Health & Science University (OHSU)
Responsible party
Huan Vo, M.D. (Principal Investigator, OHSU Knight Cancer Institute) — Principal investigator
First posted
Dec 12, 2025
Start date
Aug 24, 2026
Primary completion
May 2, 2027 (estimated)
Completion
Aug 2, 2027 (estimated)
Last update
Oct 28, 2026

Study contacts

Anh Huan Vo
principal investigator · OHSU Knight Cancer Institute

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion